• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 29th March 2021

Time to Tackle the Challenges around Combination Therapies for Cancer

A new Editorial reviews three solutions to the price and value challenge to reimbursing combination products. Higher thresholds are not justifiable. Evidence to support use of shorter regimens will take time to develop. Multi-use pricing is the best option to…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

A new Editorial reviews three solutions to the price and value challenge to reimbursing combination products. Higher thresholds are not justifiable. Evidence to support use of shorter regimens will take time to develop. Multi-use pricing is the best option to explore.

A new Editorial reviews three solutions to the price and value challenge to reimbursing combination products. Higher thresholds are not justifiable. Evidence to support the use of shorter regimens will take time to develop. Multi-use pricing is the best option to explore.

It is eight years since NICE suggested pertuzumab, when used in combination with trastuzumab and docetaxel for the treatment of HER2 positive breast cancer, might not be cost-effective, even if pertuzumab were offered at zero price. It is seven years since the NICE Decision Support Unit published analysis of how this counter-intuitive situation arises.  Combination therapies continue to come to market, often at prices presenting challenges to payers around the world. Indeed, experts agree combination therapies will become increasingly important in oncology.

A new Editorial, Not Cost-effective at Zero Price, in Expert Review of Pharmacoeconomics and Outcomes Research, sets out a broad framework for action. It builds on a workshop held in November 2019 in Australia by the not-for-profit Bellberry organisation, with invited stakeholders from around the world.  A report of the workshop was published in May 2020.

The authors, Nick Latimer, University of Sheffield, and OHE’s Adrian Towse and Chris Henshall, explain that the problem arises when the ‘backbone’ oncology drug is priced at the limit of what a payer is prepared to pay given the outcomes delivered. Willingness to pay for a new ‘add-on’ drug to backbone therapy will be limited to the additional benefit.  If the combination involves extended duration of treatment using the backbone (as with pertuzumab) as well as other extra costs, then no price may be low enough, let alone the price being sought by the developer. These challenges arise in all situations where coverage and price are linked systematically to the assessment of benefit (and not just where QALYs are used).

Three possible solutions are discussed:

1. Increase the willingness to pay for combination therapies in oncology, over and above that for monotherapy drugs. This is not supported by evidence of public or stakeholder preferences;

2. Improve the outcomes achieved by new combinations,  improving clinical development to identify optimum treatment paradigms (such as treatment durations and stopping rules that optimise health benefits and minimise adverse effects and costs). This is important but challenging. Significant progress seems unlikely in the short term;

3. Adjust the price of both constituents of a combination to reflect the value they offer when used in that combination.  This is the most feasible way forward to address the challenges of combination therapies in the near future.

Progress depends upon finding ways of aligning individual drug prices with the value attributable to them in that combination – which may be different from the value in monotherapy use or in another combination.  Where these drugs are made by the same manufacturer, it can agree to price variations with a payer to achieve this. But, usually, different manufacturers are involved and some form of explicit multi-use pricing is required. This in turn needs some way of agreeing on the value – and therefore the price – of each use.

The authors recognise the challenges in making multi-use pricing work, but conclude that it would be both beneficial and feasible for combination therapies. They go on to discuss how the value and price of each component within a combination could be determined.  Various methods have been suggested for value attribution, and work is needed to develop and assess these. But while an agreed approach to value attribution could help, the authors see the negotiation and agreement of prices as the biggest challenge. Ways need to be found to agree on prices for components from different manufacturers that add up to no more than the value-based price of the combination.  Issues to be addressed here include the role that an HTA or Payer body could and should play in instigating or joining negotiations between manufacturers, and the ways in which such negotiations could be conducted without contravening competition law.    

Where to next? A number of researchers are working on methods to attribute value to individual components in a combination.  A recent OHE/Amgen paper on this was described in an OHE blog, and a paper is expected soon from a Takeda sponsored group looking at solutions in England.

Competition law differs by country, but usually bans companies who are competitors from discussing pricing with each other. Mechanisms are therefore needed to enable companies to negotiate prices with each other that are legal within particular jurisdictions.  The Takeda sponsored group will publish a possible approach to negotiation in England.  Hopefully, this will stimulate similar work in other systems. For example, a trading platform has been proposed.

A number of assessment and payer bodies around the world are still not yet formally engaged. We believe there is a strong case for meetings involving key stakeholders in Europe, the USA, and Asia to discuss the challenges and share ideas for, and practical experience with, solutions.

Citation

Latimer, N.R., Towse A. and Henshall C. (2021): Not cost effective at zero price: valuing and paying for combination therapies in cancer, Expert Review of Pharmacoeconomics & Outcomes Research, DOI: 10.1080/14737167.2021.1879644. Available at https://doi.org/10.1080/14737167.2021.1879644  

Related Research

Towse, A., Lothgren, M., Steuten, L., and Bruce, A., 2021. Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology. OHE Consulting Report, London: Office of Health Economics. Available at: https://www.ohe.org/publications/why-we-need-new-outcomes-bashttps://www.ohe.org/publications/why-we-need-new-outcomes-based-value-attribution-framework-combination-regimensed-value-at…

Latimer N, Pollard D, Towse A, Henshall C. 2020. Challenges in valuing and paying for combination regimens in oncology. Report of an international workshop convened by Bellberry, held on November 18-20, in Sydney, Australia. May 2020. Available at https://bellberry.com.au/wp-content/uploads/Meeting-report-final-draft-May-2020.pdf

 

 

 

  • Value-Based Pricing
  • Economics of Innovation
  • Amgen

Related Insights

Slovak discounting_andrik-langfield-0rTCXZM7Xfo-unsplash_landscape
  • Insight
  • May 2023

Setting the Right Discount Rate for HTA in the Slovak Republic

Read more
Optimise_AdobeStock_576507456_landscape
  • Insight
  • April 2023

How Restrictive are NICE ‘Optimised’ Decisions?

Read more
Fishing on the lake at sunset. Fishing background.
  • Insight
  • February 2023

Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges

Read more
Cancer_WellcomeCollection_landscape
  • Insight
  • January 2023

Combination Therapies: A Step Forward to the Value Attribution Problem

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!